exoFlex
exoFlex, licence 80074736: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- exoFlex+
- Licence holder
- Aurora Nutrascience Inc.
- NPN or DIN-HM
- 80074736
- Status
- Active licence
- Licence date
- 3 January 2017
- Revision date
- 16 November 2022
- Form
- Liquide
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| (1E,6E)-1,7-Bis(4-hydroxy-3-méthoxyphényl)-1,6-heptadiène-3,5-dione Source : Curcuma longa - rhizome | 50.0 mg | Not calculated |
| (1E,6E)-1,7-Bis(4-hydroxy-3-méthoxyphényl)-1,6-heptadiène-3,5-dione Source : Curcumine | 50.0 mg | Not calculated |
| Membrane de coquille d'oeuf de poule partiellement hydrolysée Source : Partially hydrolysed chicken eggshell membrane | 450.0 mg | Not calculated |
| Membrane de coquille d'oeuf de poule partiellement hydrolysée Source : Gallus gallus - Coquille d'oeuf | 450.0 mg | Not calculated |
| Méthylsulfonylméthane Source : Sulfone de diméthyl | 300.0 mg | Not calculated |
| Boswellia serrata Source : Stem bark oleogum resin Potency : 65.0 % Boswellic acids | 200.0 mg | Not calculated |
| Vitamine C Source : Ascorbate de sodium | 50.0 mg | Not calculated |
Non-medicinal ingredients
Sorbate de potassium, Eau, glycérol, Gomme de xanthane, Stevia rebaudiana leaf extract, Lécithine, Saveur
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1.0 Cuillère à thé | 1.0 Jour(s) |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps reduce pain associated with osteoarthritis. Helps to reduce stiffness associated with osteoarthritis. Helps to relieve joint pain associated with osteoarthritis. Helps to relieve pain associated with osteoarthritis of the knee. Helps to reduce joint pain associated with osteoarthritis. Helps to reduce blood C reactive protein levels, a clinical marker of inflammation. Starts to help reduce pain at 5 days. Helps in the development and maintenance of bones. Helps in the development and maintenance of cartilage. Helps in connective tissue formation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80074736
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.